215303-72-3
215303-72-3 結構式
基本信息
RWJ 67657
JNJ 3026582
RWJ-67657
JNJ-3026582
RWJ-67657
RWJ-67657
RWJ-67657
4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-phenylpropyl)-5-(4-Pyridyl)iMidazole
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol
3-Butyn-1-ol, 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol ISO 9001：2015 REACH
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2024/08/19 | HY-15505 | 4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 | 215303-72-3 | 5mg | 800元 |
| 2024/08/19 | HY-15505 | 4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 | 215303-72-3 | 10mM * 1mLin DMSO | 880元 |
| 2024/08/19 | HY-15505 | 4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 | 215303-72-3 | 10mg | 1280元 |
常見問題列表
|
p38α 1 μM (IC 50 ) |
p38β 11 μM (IC 50 ) |
RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC
50
of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC
50
value of 13 nM.
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells.
Cell Proliferation Assay
| Cell Line: | MCF-7 breast carcinoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased colony formation. |
RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration.
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke.
| Animal Model: | The db/db mice (male, 8 weeks old) with EPCs |
| Dosage: | 50 mg/kg |
| Administration: | Administered orally; once per day for 7 consecutive days |
| Result: | Increased angiogenesis and neurogenesis of diabetic mice after cotreatment with EPCs transplantation. |